For some leukemia patients, each hour of delayed care can be the difference between life and death. JHU's Eugene Shenderov is ...

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

Acute myeloid leukemia is a type of cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer develops from myeloid blasts cells that would ...

Research subjects include neuroblastoma, Ewing's sarcoma and other common solid tumors, and childhood leukemia, especially acute lymphoblastic leukemia. The content of the article may cover the immune ...

The types of leukemia are based on whether the condition is acute (fast-growing) or chronic (slower-growing). Chronic lymphocytic leukemia (CLL) affects lymphocytes. Lymphocytes are a type of ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Further, compared to insulin use, GLP-1RA use was associated with a significantly reduced risk of lymphoid leukemia, myeloid leukemia, MPN, MDS, amyloidosis, non-Hodgkin lymphoma, monoclonal ...

Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes ...

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG+ AML is ...

The Acute-to-Chronic Workload Ratio (ACWR) is one metric you might find useful if you enjoy crunching your training numbers. This ratio has the potential to help you assess your injury risk so you ...